Nivolumab and pembrolizumab for non–small cell lung cancer
D Morgensztern, RS Herbst - Clinical Cancer Research, 2016 - AACR
The outcomes for patients with previously treated advanced stage non–small lung cancer
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
D Morgensztern, RS Herbst - Clinical cancer research: an …, 2016 - pubmed.ncbi.nlm.nih.gov
The outcomes for patients with previously treated advanced stage non-small lung cancer
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
D Morgensztern, RS Herbst - Clinical Cancer Research, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The outcomes for patients with previously
treated advanced stage non–small lung cancer (NSCLC) are very poor, with a modest …
treated advanced stage non–small lung cancer (NSCLC) are very poor, with a modest …
Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
D Morgensztern, RS Herbst - … Research: an Official Journal of the …, 2016 - europepmc.org
The outcomes for patients with previously treated advanced stage non-small lung cancer
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
D Morgensztern, RS Herbst - Clinical Cancer Research, 2016 - profiles.wustl.edu
The outcomes for patients with previously treated advanced stage non-small lung cancer
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …